MN-001 in NASH and NAFLD with Hypertriglyceridemia

Phase 2, open-label, single-arm trial of tipelukast in Nonalcoholic steatohepatitis (NASH), non-alcoholic fatty liver disease (NAFLD) and hypertriglyceridemia, sponsored by MediciNova, Inc. Primary endpoints: Mean Change From Baseline at 12 Weeks of MN-001 Treatment on Cholesterol Efflux Capacity and Mean Change From Baseline to Week 8 on Triglyceride Levels After 8 Weeks MN-001 Treatment. Started Mar 2016; status: completed.